Get the Stockscreener App
26.04
1.36%
0.35
After Hours:
25.95
-0.09
-0.35%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $26.04, with a volume of 31.75M.
It is up +1.36% in the last 24 hours and down -1.55% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.69
Open:
$25.85
24h Volume:
31.75M
Relative Volume:
0.87
Market Cap:
$148.41B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
19.96
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-0.53%
1M Performance:
-1.55%
6M Performance:
+0.04%
1Y Performance:
+12.63%
1-Day Range:
$25.79
$26.21
1-Week Range:
$25.27
$26.21
52-Week Range:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.04 | 146.42B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer-Partnered Obesity Drugmaker Eyes Deals Outside China - Bloomberg.com
Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough - Blockonomi
3 Dividend Stocks to Buy Hand Over Fist in June - The Motley Fool
Pfizer’s monthly obesity shot has side-effect profile similar to Wegovy - NewsNation
Pfizer working on 1st once-a-month anti-obesity drug - Magzter
What to know about berobenatide, Pfizer’s experimental obesity drug - AOL.com
Pfizer’s Berobenatide GLP-1 Obesity Data Might Change The Case For Investing In Pfizer (PFE) - Yahoo Finance
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. - The Motley Fool
Pfizer Revenue Recovery and Patent Cliff: Analysis as of June 2026News and Statistics - IndexBox
Comirnaty COVID-19 vaccine: what US patients should know - AD HOC NEWS
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems - Yahoo Finance
Pfizer (PFE) Advances Obesity Therapy with Promising Mid-Stage T - GuruFocus
Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy - Seeking Alpha
Pfizer targets obesity market with monthly weight-loss injection data - Investing.com
Pfizer Bets on Weight-Loss Drugs to Power Its Next Decade - Bloomberg.com
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide - The Joplin Globe
Assessing Pfizer (PFE) Valuation As Shares Recover From A Mixed Recent Performance - Yahoo Finance
Pfizer Options Spot-On: On June 5th, 143.52K Contracts Were Traded, With 2.67 Million Open Interest - Moomoo
Pfizer Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Pfizer Inc. stock (US7170811035): shares steady ahead of next catalyst as investors focus on valuati - AD HOC NEWS
Pfizer’s integrin β6 ADC advances intravesical therapy for NMIBC - BioWorld News
Pfizer licenses Chai Discovery AI platform for drug discovery - Yahoo Finance
PFIZER INC : Jefferies reaffirms its Buy rating - marketscreener.com
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit and more - Medical Marketing and Media
Pfizer signs licence agreement with Chai for AI drug discovery - Yahoo Finance
How New Multi‑Tumor Oncology Data At Pfizer (PFE) Has Changed Its Investment Story - simplywall.st
Pfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma
Diamond Blackfan Anemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, Merck KGaA - Barchart.com
Pfizer Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Pfizer Taps Chai Discovery AI To Expand Biologics Pipeline Potential - Yahoo Finance
Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report? - Yahoo Finance
Pfizer Inc stock (US7170811035): focus on oncology pipeline after Jefferies 2026 appearance - AD HOC NEWS
Pfizer to Leverage Chai Discovery’s AI Platform - Contract Pharma
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI - Yahoo Finance
Pfizer Inc. stock (US7170811035): oncology collaboration focus after Jefferies conference update - AD HOC NEWS
Southwest Securities: Innovent Bio (01801) Partners with Pfizer to Accelerate Development of Innovative Oncology Therapies - 富途牛牛
Innovent’s $10.5 billion deal marks new model for China drugmakers - thebambooworks.com
Pfizer Inc. stock (US7170811035): shares steady as investors digest oncology deal news and recent ea - AD HOC NEWS
Pfizer vs Merck: Chasing High Yield vs Higher Returns - 24/7 Wall St.
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Globe and Mail
Meet the biotech stock that's trouncing Lilly, Merck, and Pfizer in 2026 - MSN
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story - Yahoo Finance
Pfizer lifts 2022 forecast for Covid-19 vaccine sales as profits rise - Digital Journal
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal - BioWorld News
Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership? - Insider Monkey
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026 - The Globe and Mail
Why Pfizer’s Current Price May Be Too Cheap to Ignore - Yahoo Finance
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance Singapore
Pfizer’s ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story - simplywall.st
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.02%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):